Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin
- PMID: 25911110
- DOI: 10.1016/j.ejso.2015.03.233
Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin
Abstract
Background: There is no consensus on the role of postoperative chemotherapy in patients with rectal cancer who have received preoperative radio(chemo)therapy.
Materials and methods: A systematic review and meta-analysis were performed of trials that used preoperative radio(chemo)therapy and randomized patients either between postoperative chemotherapy and observation or between a fluoropyrimidine only (FU-only) and a fluoropyrimidine with oxaliplatin (FU-OXA) as postoperative chemotherapy.
Results: Five randomized studies compared postoperative chemotherapy with observation in a total of 2398 patients. None of these trials demonstrated a statistically significant benefit of chemotherapy for OS and DFS. The pooled differences in OS and DFS did not differ statistically significantly between the chemotherapy group and the observation group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were 0.95 (CI: 0.82-1.10), P = 0.49 and 0.92 (CI: 0.80-1.04), P = 0.19, respectively. In the subgroup of trials in which randomization was performed after surgery (n = 753), a statistically significant positive pooled chemotherapy effect was observed for DFS (HR = 0.79, 95% CI: 0.62-1.00, P = 0.047), but not for OS (P = 0.39). Four randomized trials compared adjuvant FU-OXA with adjuvant FU-only in 2710 patients. In two trials, the difference in DFS between groups was statistically significant in favour of FU-OXA, and in the other two trials, the difference was not significant. The pooled difference in DFS between the FU-OXA group and the FU-only group was not statistically significant: HR = 0.84 (CI: 0.66-1.06), P = 0.15.
Conclusion: The use of postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy is not based on strong scientific evidence.
Keywords: Adjuvant chemotherapy; Oxaliplatin-combination; Rectal cancer.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.Ann Oncol. 2014 Jul;25(7):1356-1362. doi: 10.1093/annonc/mdu147. Epub 2014 Apr 8. Ann Oncol. 2014. PMID: 24718885 Clinical Trial.
-
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419291 Free PMC article. Review.
-
Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.Eur J Cancer. 2013 Mar;49(4):843-51. doi: 10.1016/j.ejca.2012.09.026. Epub 2012 Oct 11. Eur J Cancer. 2013. PMID: 23063351
-
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.J Natl Cancer Inst. 2015 Sep 14;107(11):djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26374429 Free PMC article. Clinical Trial.
-
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.Colorectal Dis. 2016 Aug;18(8):763-72. doi: 10.1111/codi.13381. Colorectal Dis. 2016. PMID: 27169752 Review.
Cited by
-
Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement.Radiat Oncol J. 2024 Jun;42(2):130-138. doi: 10.3857/roj.2023.01032. Epub 2024 Jun 12. Radiat Oncol J. 2024. PMID: 38946075 Free PMC article.
-
A review of preoperative chemoradiotherapy for lower rectal cancer.J Anus Rectum Colon. 2018 May 25;1(3):65-73. doi: 10.23922/jarc.2017-013. eCollection 2017. J Anus Rectum Colon. 2018. PMID: 31583303 Free PMC article. Review.
-
Total neoadjuvant therapy in patients with locally advanced rectal cancer: A tertiary medical center experience.Mol Clin Oncol. 2021 Oct;15(4):220. doi: 10.3892/mco.2021.2382. Epub 2021 Aug 25. Mol Clin Oncol. 2021. PMID: 34476104 Free PMC article.
-
Predicting Distant Metastasis in Young-Onset Colorectal Cancer After Surgery: A Retrospective Study.Front Oncol. 2022 Feb 24;12:804038. doi: 10.3389/fonc.2022.804038. eCollection 2022. Front Oncol. 2022. PMID: 35280740 Free PMC article.
-
Long non-coding RNA HOXA-AS3 facilitates the malignancy in colorectal cancer by miR-4319/SPNS2 axis.J Physiol Biochem. 2021 Nov;77(4):653-666. doi: 10.1007/s13105-021-00832-x. Epub 2021 Oct 21. J Physiol Biochem. 2021. PMID: 34671931
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources